ReviewInternational journal of ophthalmology2017
Intraocular lymphoma.
Review in International journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 38 citations in OpenAlex.
- Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?Journal of clinical and experimental hematopathology : JCEH · 2019Trial
- The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa).American journal of hematology · 2026Observational
- Report of a case of nasal-type extranodal NK/T-cell lymphoma with ciliary body involvement and literature review of interleukin-10 and interleukin-6 in intraocular T-cell lymphoma.American journal of ophthalmology case reports · 2025Article
- Aqueous humor biomarkers in ocular oncology: Insights and advances.Cell reports. Medicine · 2025Review
- A case of primary intraocular B-cell lymphoma masquerading alongside varicella-zoster virus retinitis.American journal of ophthalmology case reports · 2025Article
- Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.Blood science (Baltimore, Md.) · 2025Review
- Primary Intraocular Lymphoma: Rad-Path and Ophthalmologic Correlation.AJNR. American journal of neuroradiology · 2025Article
- Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025Review
- Neurosurgical Management of Central Nervous System Lymphoma: Lessons Learnt from a Neuro-Oncology Multidisciplinary Team Approach.Journal of personalized medicine · 2023Article
- Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma.Ocular immunology and inflammation · 2023Observational
- Value of Combined Diagnosis for Choroidal Lymphoma: A Case Report.Current oncology (Toronto, Ont.) · 2022Article
- Diagnostic Accuracy of Vitreous Cytology in Patients with Vitreoretinal Lymphoma.Journal of clinical medicine · 2022Article
- Review
- A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments.Journal of clinical medicine · 2022Review
- Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives.International journal of molecular sciences · 2022Review
- Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.Medicina (Kaunas, Lithuania) · 2022Review
- Primary central nervous system lymphoma presenting as a single choroidal lesion mimicking metastasis: A case report.World journal of clinical cases · 2022Article
- Article
- Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology.Current oncology (Toronto, Ont.) · 2022Article
- MALT Lymphoma Presenting with Peripheral Ulcerative Keratitis.International medical case reports journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraocular lymphoma (IOL) is a rare lymphocytic malignancy which contains two main distinct forms. Primary intraocular lymphoma (PIOL) is mainly a sub-type of primary central nervous system lymphoma (PCNSL). Alternatively, IOL can originate from outside the central nervous system (CNS) by metastasizing to the eye. These tumors are known as secondary intraocular lymphoma (SIOL). The IOL can arise in the retina, uvea, vitreous, Bruch's membrane and optic nerve. There are predominantly of B-cell origin; however there are also rare T-cell variants. Diagnosis remains challenging for ophthalmologists and pathologists, due to its ability to masquerade as noninfectious or infectious uveitis, white dot syndromes, or occasionally as other metastatic cancers. Laboratory tests include flow cytometry, immunocytochemistry, interleukin detection (IL-10: IL-6, ratio >1), and polymerase chain reaction (PCR) amplification. Methotrexate-based systemic chemotherapy with external beam radiotherapy and intravitreal chemotherapy with methotrexate are useful for controlling the disease, but the prognosis remains poor. Therefore, it is important to make an early diagnose and treatment. This review is focused on the clinical manifestations, diagnosis, treatment and prognosis of the IOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.